NCT06765902View on ClinicalTrials.gov

Immunotherapy Before and After Surgery

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

January 31, 2031

Study Completion Date

June 30, 2031

Conditions
High-risk Prostate Cancer
Interventions
DRUG

N-803

A subcutaneous injection of an IL-15 superagonist.

DRUG

ETBX-071

A subcutaneous injection of a prostate-specific antigen (PSA) adenovirus vaccine.

DRUG

M-CENK

An intravenous infusion of the patient's own NK cells that have been expanded and activated in a laboratory.

Sponsors

Lead Sponsor

ImmunityBio, Inc.
All Listed Sponsors
lead

ImmunityBio, Inc.

INDUSTRY

NCT06765902 - Immunotherapy Before and After Surgery | Biotech Hunter | Biotech Hunter